P
Pei-Yu Yan
Researcher at Macau University of Science and Technology
Publications - 20
Citations - 363
Pei-Yu Yan is an academic researcher from Macau University of Science and Technology. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 3, co-authored 10 publications receiving 38 citations.
Papers
More filters
Journal ArticleDOI
Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy.
Ju-Min Huang,Di Liu,Yuwei Wang,Liang Liu,Jian Li,Jing Yuan,Zhi-Hong Jiang,Ze-Bo Jiang,W.L. Wendy Hsiao,Haizhou Liu,Imran Khan,Ying Xie,Jian-Lin Wu,Ya-Jia Xie,Yi-Zhong Zhang,Yu Fu,Junyi Liao,Wen-Jun Wang,Huan-Ling Lai,A-Xi Shi,Jun Cai,Lian-Xiang Luo,Run-Ze Li,Xiao-Jun Yao,Xing-Xing Fan,Qibiao Wu,Zhongqiu Liu,Pei-Yu Yan,Jing-Guang Lu,Ming-Rong Yang,Lin Wang,Yabing Cao,Hong Wei,Elaine Lai-Han Leung +33 more
TL;DR: In this paper, the combination treatment of ginseng polysaccharides (GPs) and αPD-1 monoclonal antibody (mAb) could sensitise the response by modulating gut microbiota.
Journal ArticleDOI
Early lung cancer diagnostic biomarker discovery by machine learning methods.
Ying Xie,Wei-Yu Meng,Run-Ze Li,Yuwei Wang,Xin Qian,Chang Chan,Zhi-Fang Yu,Xing-Xing Fan,Hudan Pan,Chun Xie,Qibiao Wu,Pei-Yu Yan,Liang Liu,Yijun Tang,Xiao-Jun Yao,Meifang Wang,Elaine Lai-Han Leung,Elaine Lai-Han Leung +17 more
TL;DR: An interdisciplinary mechanism combines metabolomics and machine learning methods to improve lung cancer survival rate and the availability of blood-based screening could increase lung cancer patient uptake.
Journal ArticleDOI
Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer.
Ze-Bo Jiang,Wen-Jun Wang,Cong Xu,Ya-Jia Xie,Xuan-Run Wang,Yi-Zhong Zhang,Ju-Min Huang,Min Huang,Chun Xie,Pei Liu,Xing-Xing Fan,Yupo Ma,Pei-Yu Yan,Liang Liu,Xiao-Jun Yao,Qibiao Wu,Elaine Lai-Han Leung +16 more
TL;DR: In this paper, the effects and underlying mechanisms of luteolin, apigenin, and anti-PD-1 antibody combined with luteolins or apigenins on the PD-L1 expression and anti tumorigenesis in KRASmutant lung cancer were investigated.
Journal ArticleDOI
Metabolomics and integrated network pharmacology analysis reveal Tricin as the active anti-cancer component of Weijing decoction by suppression of PRKCA and sphingolipid signaling
Jia-Xin Li,Run-Ze Li,Ao Sun,Hua Zhou,Erwin Neher,Jia-Shun Yang,Ju-Min Huang,Yi-Zhong Zhang,Ze-Bo Jiang,Tu-Liang Liang,Lin-Rui Ma,Jian Wang,Xuan-Run Wang,Xiao-Qing Fan,Jie Huang,Ying Xie,Liang Liu,Ling Tang,Elaine Lai-Han Leung,Pei-Yu Yan +19 more
TL;DR: Wang et al. as mentioned in this paper investigated the pharmacological treatment mechanism of Weijing decoction in treating NSCLC via an integrated model of network pharmacology, metabolomics and biological methods.
Journal ArticleDOI
Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non–Small Cell Lung Cancer:
TL;DR: This review mainly focuses on introducing existing monoclonal antibodies containing nivolumab, pembrolizumabs, atezolizumAB, avelumab and durvalumab along with 3 ordinary biomarkers such as PD-L1 expression, tumor mutation burden, and microsatellite instability.